Nasdaq gnlx.

On September 12, 2023, 10% owner Aladar Szalay sold 52,616 shares of Genelux Corp ( NASDAQ:GNLX ). This move comes amidst a year where the insider has sold a total of 89,893 shares and purchased ...Nov 14, 2023 · WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ... Jun 29, 2023 · WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ... Genelux is a publicly-traded biopharmaceutical company (Nasdaq: GNLX). It currently is conducting a Phase 3 registrational trial in resistant/refractory ...

Genelux Corporation (NASDAQ:GNLX) fell 8.1% to $5.65. Genelux announced pricing of $15 million initial public offering of 2.5 million shares of common stock at a price of $6 per share.The average one-year price target for Genelux (NASDAQ:GNLX) has been revised to 35.02 / share. This is an increase of 8.99% from the prior estimate of 32.13 dated August 31, 2023.WebGenelux Co. ( NASDAQ:GNLX – Free Report) – Analysts at HC Wainwright issued their FY2023 earnings per share (EPS) estimates for shares of Genelux in a report released on Monday, November 27th ...Web

Genelux Corp (NASDAQ: GNLX) has experienced a rise in its stock price by 11.85 compared to its previous closing price of 10.46. However, the company has seen a gain of 12.72% in its stock price over the last five trading days. GlobeNewsWire reported 2023-09-07 that WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) — Genelux […]

In terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...Uncover the latest insider trading activity for Genelux Corporation (GNLX). Know which insiders are buying and selling along with top shareholders and ownership breakdown. Dashboard Markets Discover Watchlist Portfolios Screener. Genelux Corporation. NasdaqCM:GNLX Stock Report. Mkt Cap: US$317.1m. Add to watchlist.WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...

WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug ...

View live Genelux Corporation chart to track its stock's price action. Find market predictions, GNLX financials and market news.

Genelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile News Charts Forecasts Financials... Posted by Techdows on Nov 28th, 2023. HC Wainwright initiated coverage on shares of Genelux ( NASDAQ:GNLX – Free Report) in a research note issued to investors on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $35.00 target price on the stock. A number of other brokerages also recently …WebGenelux Corporation ( Nasdaq: GNLX ), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering ...GNLX Genelux Corporation Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesGenelux ( NASDAQ: GNLX) is a recently IPO-ed phase 3 stage cancer therapeutics company. Its business is designing “oncolytic viral immunotherapies that are designed to generate a personalized ...Web

WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug ...WebWESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...WebWESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...If you're new to stock investing, here's how to buy Genelux stock. What is the 52 week high and low for Genelux (NASDAQ: GNLX)? (NASDAQ: GNLX) Genelux's 52-week high was $40.98, and its 52-week low was $5.35. It is currently -57.93% from its 52-week high and 222.24% from its 52-week low.Check if GNLX Stock has a Buy or Sell Evaluation. GNLX Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Genelux Corporation News.Genelux Corporation Common Stock (GNLX) Nasdaq Listed; Nasdaq 100; Data is currently not available. Bid: Ask: Volume: 0. ... anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...

Nov 24, 2023 · Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian ...

GNLX Genelux Corporation Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian CancerThe average one-year price target for Genelux (NASDAQ:GNLX) has been revised to 35.02 / share. This is an increase of 8.99% from the prior estimate of 32.13 dated August 31, 2023.Web20. 11. 2023 ...View live Genelux Corporation chart to track its stock's price action. Find market predictions, GNLX financials and market news.GNLX | Complete Genelux Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Follow. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ...WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...

Check if GNLX Stock has a Buy or Sell Evaluation. GNLX Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Genelux Corporation News.

Explore new charts. Discover historical prices for GNLX stock on Yahoo Finance. View daily, weekly or monthly format back to when Genelux Corporation stock was issued.

WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...HC Wainwright started coverage of Genelux ( NASDAQ: GNLX) with a buy rating, stating that it believed the company’s lead oncolytic virus Olvi-Vec is “underappreciated” and could lead to a ...Find the latest Financials data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.American International Group Inc. bought a new position in Genelux Co. (NASDAQ:GNLX – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,332 shares of the company’s stock, valued at approximately $44,000. A number of other institutional investors also recently modified their […]On September 18, 2023, John Thomas, a director at Genelux Corp ( NASDAQ:GNLX ), sold 6,667 shares of the company. This move comes amidst a year where the insider has sold a total of 6,667 shares ...On September 12, 2023, 10% owner Aladar Szalay sold 52,616 shares of Genelux Corp ( NASDAQ:GNLX ). This move comes amidst a year where the insider has sold a total of 89,893 shares and …Genelux ( NASDAQ: GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer. The company is currently ...Check if GNLX Stock has a Buy or Sell Evaluation. GNLX Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Genelux Corporation News.

Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the Nasdaq under the symbol GNLX. With 2.5 million ...WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...Back to GNLX Overview. Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or ...Instagram:https://instagram. schwab personalized indexingsrugdollar10000 dollar billhigh dividend blue chip stocks Genelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile News Charts Forecasts Financials... qqqm dividend yieldstocks short squeeze Aug 14, 2023 · WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ... WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...Web stock market month Oncolytic immunotherapy is an immunotherapy modality where viruses selectively replicate and kill tumor cells while leaving normal cells intact. Viral cell killing has the potential to expose all the tumor’s neoantigens to the immune system and to establish long-term antitumor immunity to improve outcomes for cancer patients. LEARN MORE.Gold -0.10(-0.00%) Genelux Corporation (GNLX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 10.38 -0.34 (-3.17%) At close: 04:00PM EST 10.64 +0.26 (+2.50%) After hours:... Genelux Co. ( NASDAQ:GNLX – Free Report) – Analysts at HC Wainwright issued their FY2023 earnings per share (EPS) estimates for shares of Genelux in a …